Thermo Fisher Scientific (NYSE:TMO) VP Lisa Britt Sells 10,225 Shares

Thermo Fisher Scientific Inc. (NYSE:TMO) VP Lisa Britt sold 10,225 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares in the company, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Thermo Fisher Scientific Trading Up 0.9%

Shares of NYSE TMO traded up $4.87 during mid-day trading on Monday, hitting $577.28. The company’s stock had a trading volume of 1,376,380 shares, compared to its average volume of 2,375,255. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company’s fifty day simple moving average is $518.58 and its 200-day simple moving average is $462.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market cap of $216.89 billion, a price-to-earnings ratio of 33.35, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the business posted $5.28 earnings per share. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Finally, UBS Group upped their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $601.65.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the stock. Financial Management Network Inc. grew its stake in shares of Thermo Fisher Scientific by 3.7% in the third quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock valued at $248,000 after buying an additional 18 shares in the last quarter. Bruce G. Allen Investments LLC lifted its stake in Thermo Fisher Scientific by 8.8% in the third quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 19 shares during the last quarter. White Pine Capital LLC increased its stake in shares of Thermo Fisher Scientific by 3.2% during the 3rd quarter. White Pine Capital LLC now owns 611 shares of the medical research company’s stock worth $296,000 after purchasing an additional 19 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 35.1% in the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Finally, Hopwood Financial Services Inc. grew its holdings in Thermo Fisher Scientific by 9.1% during the third quarter. Hopwood Financial Services Inc. now owns 239 shares of the medical research company’s stock worth $116,000 after purchasing an additional 20 shares during the period. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.